Although the pyrotinib group outperformed the control group in terms of bpCR, this difference did not reach statistical significance, possibly due to the limited sample size.
← all excerpts
The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study
1
—
—